Noble sitting on historical support resistance zone

Resting inside $1.88 - $1.85 support zone.

This support zone was tested on 23rd Nov 2007 and price rebounded from $1.88 until $2.49.

Monitor breakout direction.

.

Applera Corporation - Celera Genomics Group

Company information

Applera Corporation was incorporated in 1998 under the laws of the State of Delaware. Applera Corporation conducts business through three business segments: Applied Biosystems Group, Celera Genomics Group and Celera Diagnostics. Applied Biosystems serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Its customers use these products and services to analyze nucleic acids, small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems' products and services are designed to address the demand for increased automation and efficiency in pharmaceutical and biotechnology laboratories by combining the detection capabilities of analytical instruments with advances in automation and laboratory work-flow design. There are no specialized raw materials that are particularly essential to the operation of Applied Biosystems' business.

Applied Biosystems' products are based on complex, rapidly developing technologies. Some of these technologies are covered by patents owned by Applied Biosystems, and others are owned by third parties and are used by Applied Biosystems under license. Applied Biosystems faces federal, state, and local laws and regulations regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, in those jurisdictions where Applied Biosystems operates or maintains facilities.

Celera Genomics is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune, and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. Celera Genomics expects to use these capabilities, along with its molecular and cell biology, medicinal and computational chemistry, pharmacology, and other drug development technologies to optimize the potency, selectivity, and physical properties of new drug candidates.

Celera Genomics' operations require a variety of raw materials, such as chemical and biochemical materials and other supplies, some of which are occasionally found to be in short supply. Through its internal research programs and collaborative programs, Celera Genomics has developed and anticipates that it will further develop an increasing portfolio of intellectual property.

Celera Genomics faces federal, state, and local laws and regulations regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, in those jurisdictions where Celera Genomics operates or maintains facilities. Celera Diagnostics is engaged principally in the discovery, development, and commercialization of diagnostic products. In particular, Celera Diagnostics is studying SNPs and gene expression patterns in human biological tissues and blood samples and their association with specific common, complex diseases. These SNPs and gene expression patterns are often referred to as genetic markers.

Celera Diagnostics' gene-disease association studies are currently focused on the following disease areas: heart disease; breast cancer; Alzheimer's disease; autoimmune and inflammatory diseases, including rheumatoid arthritis; liver disease; and diabetes. Celera Diagnostics' operations require a variety of raw materials, such as chemical and biochemical materials, and other supplies, some of which are occasionally found to be in short supply.

Celera Diagnostics faces federal, state, and local laws and regulations regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, in those jurisdictions where Celera Diagnostics operates or maintains facilities. As of the end of its 2005 fiscal year, Applera had approximately 4,930 employees

http://money.cnn.com/quote/snapshot/snapshot.html?symb=CRA

Lian Beng Volume Distribution Chart

BB bought in morning and sold in the afternoon.

BB selling to retailers in the afternoon.

Trade with caution.